Boan Biotech Announces 2026 Interim Results

Innovating & transforming full steam aheadGlobal Commercialization Poised for GrowthYantai, China, August 27, 2026 — Boan Biotech (6955.HK) today announced its interim results for the first half ...

DISCLOSEABLE TRANSACTION FINANCE LEASE AGREEMENT

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

IND Application for Boan Biotech’s TL1A/IL-23 Bispecific Antibody BA2201 Accepted in China

Boan Biotech today announced that the Investigational New Drug (IND) application for BA2201 has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administr...

VOLUNTARY ANNOUNCEMENT CDE ACCEPTANCE OF IND APPLICATION FOR TL1A/IL-23 BISPECIFIC ANTIBODY BA2201

Boan Biotech Announces Successful Completion of Phase Ia Clinical Trial of BA1302 (CD228-Directed ADC) in China

Objective Responses observed in multiple types of advanced solid tumors, showing potential to treat a variety of cancersBoan Biotech today announced the completion of the monotherapy dose-escalation p...

VOLUNTARY ANNOUNCEMENT COMPLETION OF PHASE IA CLINICAL TRIAL OF BA1302 (CD228-DIRECTED ADC) IN CHINA

INSIDE INFORMATION ANNOUNCEMENT PROFIT WARNING

NOTICE OF BOARD MEETING

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2026